Related Experiment Videos
Pharmacokinetic considerations in the development of peptide-based imaging agents
J Lister-James1, B R Moyer, R T Dean
1Diatide Inc., Londonderry, NH 03053, USA.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)
|June 1, 1997
Abstract:
Pharmacokinetic factors to be considered in the development of peptide-based imaging agents are reviewed. These include size, plasma protein binding, lipophilicity, resistance or susceptibility to proteolysis and radiolabel integrity. These factors are discussed in the context of several examples of thrombus and tumor imaging agents either commercially available or in development.